Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Linda K.S. Leung"'
Autor:
Carlos K. H. Wong, Herbert Ho-Fung Loong, Sampson Sui Chun Kwan, Y.-M. Lau, Gordon C.H. Tang, Linda K.S. Leung, Teresa Tse, Yingjun Zhang, Yihui Wei
Publikováno v:
ESMO Open
ESMO Open, Vol 5, Iss 6 (2020)
ESMO Open, Vol 5, Iss 6 (2020)
Background The prognostic impact of comorbidities in patients with sarcomas is not well defined. The aims of this study were to examine the implications of comorbidities and abnormal peripheral blood indices in patients with sarcomas.Methods A popula
Autor:
Meaghan Gibbs, Linda K.S. Leung, Andrea Chang, Zheng-Yi Zhou, Carlos K. H. Wong, Jipan Xie, Catherine P. K. Chan, Herbert H. Loong
Publikováno v:
Cost Effectiveness and Resource Allocation : C/E
Cost Effectiveness and Resource Allocation, Vol 18, Iss 1, Pp 1-9 (2020)
Cost Effectiveness and Resource Allocation, Vol 18, Iss 1, Pp 1-9 (2020)
Introduction Lower-dose ceritinib (450 mg) once-daily with food was approved in 2018 in Hong Kong (HK) for first-line treatment of patients with anaplastic lymphoma kinase-positive (ALK +) advanced non-small cell lung cancer (NSCLC). This study exami
Autor:
Raquel Aguiar-Ibáñez, Jason Jen, S. C. Tan, Mary Y.K. Lee, Herbert H. Loong, Carlos K. H. Wong, Jingshu Wang, Linda K.S. Leung
Publikováno v:
Cost Effectiveness and Resource Allocation : C/E
Cost Effectiveness and Resource Allocation, Vol 18, Iss 1, Pp 1-14 (2020)
Cost Effectiveness and Resource Allocation, Vol 18, Iss 1, Pp 1-14 (2020)
Background Pembrolizumab has been shown to improve overall survival (OS) and progression free survival (PFS) compared to ipilimumab in patients with ipilimumab-naïve advanced melanoma; however, there are no published data on the cost-effectiveness f
Publikováno v:
Clinical Gastroenterology and Hepatology. 19:e70
Autor:
Ann D. King, Charles Ming Lok Chan, Wing M. Ho, Anthony T.C. Chan, A. Poon, Linda K.S. Leung, Frankie Kf Mo, Sze Chuen Cesar Wong, Ki Wang, Brigette B.Y. Ma
Publikováno v:
Annals of Oncology. 28:1576-1581
Background This study investigated the predictive and prognostic significance of assessing early drug response with both positron-emission computerized tomography (PET-CT) and circulating tumor cells (CTCs) in patients receiving first-line chemothera
Autor:
Herbert H. Loong, Z-Y. Zhou, Wenxi Tang, A. Chang, C.P.K. Chan, Linda K.S. Leung, M. Gibbs, Carlos Kh Wong
Publikováno v:
Annals of Oncology. 31:S1394-S1395
Autor:
Kenneth C.W. Wong, Brigette B.Y. Ma, K.W.C. Lee, T.-C. Chan, J. Fung, Ka Fai To, K. Ho, A.C.Y. Wong, Daisy Cm Lam, Chit Chow, Winnie Yeo, Herbert H. Loong, Linda K.S. Leung, Stephen L. Chan, Jane Koh, Edwin P. Hui, S.-T. Mok
Publikováno v:
Annals of Oncology. 30:ix124-ix125
Background Molecular profiling of tumour tissue to guide treatment of patients (pts) with advanced solid tumours has previously been reported. Most series were reported from large volume academic cancer centres in the West. There is a paucity of data
Autor:
T. Tan, Linda K.S. Leung, Teresa Tse, S.C.S. Kwan, Carlos Kh Wong, C.-W. Ho, Y.Z. Zhang, Y.-M. Lau, Herbert H. Loong
Publikováno v:
Annals of Oncology. 30:ix135-ix136
Background Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have been shown to be prognostic in various cancers. Prior reports of this in sarcomas have predominantly been made through smaller cohorts from single institutions. We
Autor:
Brigette B.Y. Ma, Yuk Ming Dennis Lo, Anthony T.C. Chan, Sing Fai Leung, Frankie Kf Mo, Edwin P. Hui, Kwan Chee Chan, Linda K.S. Leung, Benny Zee, K. W. Chu, Kathy Chow
Publikováno v:
Annals of Oncology. 25:1204-1208
BACKGROUND To test the hypothesis that prognostication of treatment outcome is feasible by biomarker response at midcourse of chemoradiotherapy (CRT)/radiotherapy (RT), with respect to the plasma load of Epstein-Barr viral (EBV) DNA in nasopharyngeal
Autor:
Y.-M. Lau, Linda K.S. Leung, Carlos Kh Wong, Sui-chun Sampson Kwan, Teresa Tse, C.-W. Ho, Herbert H. Loong
Publikováno v:
Annals of Oncology. 30:v691
Background The aims of this study were to understand the prevalence of chemotherapy (chemo) use and its associated impact on survival in patients (pts) with either bone- and soft-tissue sarcomas (STS) through a large real-world population dataset. Me